We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




AI Model Outperforms Clinicians in Rare Disease Detection

By LabMedica International staff writers
Posted on 04 Mar 2026

Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. More...

Many conditions present with heterogeneous signs that overlap with common disorders, leading to repeated referrals, misdiagnosis, and unnecessary procedures. For many patients, time to a confirmed diagnosis can exceed five years. A new study now shows that an artificial intelligence (AI) system can outperform experienced clinicians in identifying rare diseases earlier and more accurately.

A team led by researchers at Shanghai Jiao Tong University and affiliated institutions has developed DeepRare, an agentic framework for rare-disease prioritization and diagnosis. Rather than relying on a single model, the system coordinates 40 specialized digital tools to analyze diverse inputs, including a patient’s DNA, official medical databases, and handwritten clinical notes. A central AI host orchestrates these components to synthesize evidence and converge on a diagnosis with traceable reasoning.

DeepRare was first evaluated on 6,401 clinical cases with known outcomes. Using the same symptom and DNA information available to the original clinicians years earlier, the system could have identified the correct condition earlier in the diagnostic process. In this retrospective benchmark, it also outperformed 15 existing diagnostic systems.

A subsequent head-to-head assessment tested DeepRare against physicians on 163 difficult cases. Five experienced doctors, each with more than a decade of practice, received the same data as the system. DeepRare achieved a 64.4% top-1 diagnostic accuracy on the first attempt, compared with 54.6% for the physicians.

Even when not exactly correct on the first try, the model’s Recall@3 indicated that the right diagnosis was usually among its top three suggestions. Ten rare-disease specialists reviewed the system’s step-by-step reasoning and agreed with its logic 95.4% of the time. The findings were detailed in a study published in Nature on February 18, 2026.

"DeepRare is one of the first computational models to surpass the diagnostic performance of expert physicians in the complex task of rare-disease phenotyping and diagnosis," stated the study's authors. "Our work not only advances rare disease diagnosis but also demonstrates how the latest powerful large-language-model-driven agentic systems can reshape current clinical workflows."

Related Links:
Shanghai Jiao Tong University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Urinalysis Solution
UN-9000
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.